Related Experiment Video

Updated: Jun 18, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Drug design with Cdc7 kinase: a potential novel cancer therapy target

Masaaki Sawa1, Hisao Masai

  • 1Carna Biosciences Inc., Kobe, Japan.

Drug Design, Development and Therapy
|November 19, 2009
PubMed

Insights

Researchers identified Cdc7 kinase as a novel target for cancer therapy. Inhibiting this kinase selectively kills cancer cells while sparing normal cells, showing promise for new treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Novel molecular targets are crucial for developing effective cancer therapies.
  • Kinases are frequently targeted in cancer drug development.
  • Cell cycle progression is regulated by kinases, with some being investigated for cancer treatment.

Purpose of the Study:

  • To identify novel molecular targets for cancer therapy.
  • To investigate the role of Cdc7 kinase in cancer cell proliferation and survival.

Main Methods:

  • Inhibition of Cdc7 kinase using low-molecular-weight compounds.
  • Assessment of effects on cancer cell cycle progression, DNA damage, and cell death.
  • Evaluation of tumor growth inhibition in animal models.

Main Results:

  • Cdc7 kinase inhibition retards cancer cell S phase progression and induces DNA damage.
  • Cdc7 inhibition leads to p53-independent cell death in cancer cells.
  • Normal cell viability is not significantly affected by Cdc7 inhibition.
  • Low-molecular-weight Cdc7 inhibitors (IC50 < 10 nM) demonstrated tumor growth inhibition in vivo.

Conclusions:

  • Cdc7 kinase is a promising novel molecular target for cancer therapy.
  • Selective inhibition of Cdc7 kinase offers a potential therapeutic strategy with minimal impact on normal cells.
Keywords:
ATP-binding pocketCdc7 kinaseDNA damagescell cyclegenome stabilitykinase inhibitorreplication fork

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...